Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Japanese cedar pollen allergen extract
- Development stage
- Unknown
- Lead developer
- Torii Pharmaceutical
- Modality
- Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Sublingual
01
Overview
Japanese cedar allergen tablet is a sublingual immunotherapy (SLIT) designed for the treatment of allergic rhinitis caused by Japanese cedar (*Cryptomeria japonica*) pollen. Developed by ALK-Abelló and marketed in Japan by Torii Pharmaceutical as CEDARCURE, the tablet contains standardized allergen extracts from Japanese cedar pollen. The mechanism of action involves regular sublingual administration to induce immune tolerance, shifting the immune response from a Th2-mediated allergic reaction to a Th1/Treg-mediated tolerant state. This process reduces the production of allergen-specific IgE and increases the production of protective IgG4 antibodies, thereby alleviating symptoms such as sneezing, rhinorrhea, and nasal congestion.
- Brand names
- CEDARCURE
- Other names
- Japanese cedar allergen tabletJapanese cedar pollen sublingual tabletJCP-SLIT
02
Targets
Pectate lyase Cry j 1Cry j 2
Beyond the preview
Go deeper on Japanese cedar pollen allergen extract.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Japanese cedar pollen allergen extract.